Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Iovance Biotherapeutics Inc IOVA

Healthcare Biotechnology
Iovance Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company develops and delivers tumor infiltrating lymphocyte (TIL), therapies for patients with solid tumor cancers. Its lead product candidate, Amtagvi (lifileucel), is a tumor-derived autologous T cell immunotherapy indicated for the treatment of adult patients with unresectable or metastatic melanoma previously... see more

Recent & Breaking News (NDAQ:IOVA)

Iovance Biotherapeutics to Host First Quarter 2023 Financial Results Conference Call and Webcast on Tuesday, May 9, 2023

GlobeNewswire May 2, 2023

Iovance Biotherapeutics to Present at Upcoming Conferences

GlobeNewswire April 24, 2023

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Iovance Biotherapeutics, Inc. (NASDAQ: IOVA)

PR Newswire April 19, 2023

Iovance Biotherapeutics Completes Biologics License Application (BLA) Submission for Lifileucel in Advanced Melanoma

GlobeNewswire March 24, 2023

Iovance Biotherapeutics to Present at Upcoming Conferences

GlobeNewswire March 1, 2023

Iovance Biotherapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Corporate Updates

GlobeNewswire February 28, 2023

Iovance Biotherapeutics to Host Fourth Quarter and Full Year 2022 Financial Results Conference Call and Webcast on Tuesday, February 28, 2023

GlobeNewswire February 21, 2023

Iovance Biotherapeutics Provides Corporate, Clinical, and Regulatory Updates

GlobeNewswire January 23, 2023

Iovance Biotherapeutics to Present at Upcoming Conferences

GlobeNewswire November 30, 2022

Iovance Biotherapeutics Provides Update on Biologics License Application Submission for Lifileucel in Advanced Melanoma

GlobeNewswire November 18, 2022

Iovance Biotherapeutics Announces Updated Clinical Data for Lifileucel in Advanced Melanoma at Society for Immunotherapy of Cancer (SITC) Annual Meeting

GlobeNewswire November 10, 2022

Iovance Biotherapeutics Announces Updated Clinical Data for Lifileucel in Advanced Melanoma at Society for Immunotherapy of Cancer (SITC) Annual Meeting

GlobeNewswire November 7, 2022

Iovance Biotherapeutics Reports Third Quarter and Year-to-Date 2022 Financial Results and Corporate Updates

GlobeNewswire November 3, 2022

Iovance Biotherapeutics to Host Third Quarter Financial Results Conference Call and Webcast on Thursday, November 3, 2022

GlobeNewswire October 24, 2022

Iovance Biotherapeutics Announces First Patient Dosed with PD-1 Inactivated Tumor Infiltrating Lymphocyte (TIL) Therapy

GlobeNewswire October 10, 2022

Iovance Biotherapeutics to Present Clinical Data for Lifileucel Tumor Infiltrating Lymphocyte (TIL) Therapy in Advanced Melanoma at Society for Immunotherapy of Cancer's (SITC) 37th Annual Meeting

GlobeNewswire October 5, 2022

Cara Therapeutics Appoints Ryan Maynard as Chief Financial Officer

GlobeNewswire September 12, 2022

Iovance Biotherapeutics to Present at Upcoming Conferences

GlobeNewswire September 6, 2022

Iovance Biotherapeutics to Present Posters at ESMO 2022

GlobeNewswire September 6, 2022

Iovance Biotherapeutics Initiates Biologics License Application (BLA) Submission for Lifileucel in Advanced Melanoma

GlobeNewswire August 25, 2022